EGFR tyrosine kinase inhibitors (TKIs) for adjuvant therapy of early-stage non-small cell lung cancer (NSCLC): ready for the clinic?

por Steuer, Conor E., Ramalingam, Suresh S.
Publicado 2020

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC

por Osta, Badi El, Ramalingam, Suresh S.
Publicado 2020

Neoadjuvant therapy gains FDA approval in non-small cell lung cancer

por Leal, Ticiana A., Ramalingam, Suresh S.
Publicado 2022

Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury

por Rice, Shawn J., Hyland, Victoria, Behera, Madhusmita, Ramalingam, Suresh S., Bunn, Paul, Belani, Chandra P.
Publicado 2020

Bevacizumab’s Association With a Decreased Risk of Brain Metastases in ECOG-ACRIN E1505, a Phase 3 Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab in Surgical...

por Varlotto, John M., Wang, Yating, Sun, Zhuoxin, Wakelee, Heather A., Ramalingam, Suresh, Schiller, Joan
Publicado 2022

Engagement and outcomes of cancer patients referred to a tobacco cessation program at a National Cancer Institute‐designated cancer center

por Westergaard, Sarah A., Rupji, Manali, Franklin, Lauren E., Behera, Madhusmita, Ramalingam, Suresh S., Higgins, Kristin A.
Publicado 2022

Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions

por Marullo, Rossella, Werner, Erica, Degtyareva, Natalya, Moore, Bryn, Altavilla, Giuseppe, Ramalingam, Suresh S., Doetsch, Paul W.
Publicado 2013

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth

por Koo, Junghui, Wang, Xuerong, Owonikoko, Taofeek K., Ramalingam, Suresh S., Khuri, Fadlo R., Sun, Shi-Yong
Publicado 2015

Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer

por Vishwanathan, Karthick, Cantarini, Mireille, So, Karen, Masson, Eric, Fetterolf, Jennifer, Ramalingam, Suresh S., Harvey, R. Donald
Publicado 2019

GSK3 is required for rapalogs to induce degradation of some oncogenic proteins and to suppress cancer cell growth

por Koo, Junghui, Wang, Xuerong, Owonikoko, Taofeek K., Ramalingam, Suresh S., Khuri, Fadlo R., Sun, Shi-Yong
Publicado 2021

Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells

por Webber, Philip J., Park, Chanhee, Qui, Min, Ramalingam, Suresh S., Khuri, Fadlo R., Fu, Haian, Du, Yuhong
Publicado 2015

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

por Zang, Hongjing, Qian, Guoqing, Arbiser, Jack, Owonikoko, Taofeek K., Ramalingam, Suresh S., Fan, Songqing, Sun, Shi‐Yong
Publicado 2020

The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations

por Shi, Puyu, Zhang, Shuo, Zhu, Lei, Qian, Guoqing, Ren, Hui, Ramalingam, Suresh S., Chen, Mingwei, Sun, Shi-Yong
Publicado 2019

An insight into the mental health needs of the common public of Tamil Nadu, India, subjected to COVID-19 lockdown, a rare unprecedented crisis

por Rajendran, Karthikeyan Pandiyambakkam, Govindarajulu, Srinivas, Adaikalam, Joseph Maria, Srinivasan, Valarmathi, Seshayyan, Sudha, Ramalingam, Suresh, Elangovan, Arvind Raj
Publicado 2022

The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity against Non-Small Cell Lung Cancer In Vitro and In Vivo

por Xu, Cheng-Xiong, Li, Yikun, Yue, Ping, Owonikoko, Taofeek K., Ramalingam, Suresh S., Khuri, Fadlo R., Sun, Shi-Yong
Publicado 2011

Multiplexed protein profiling reveals spatial subcellular signaling networks

por Cai, Shuangyi, Hu, Thomas, Venkatesan, Mythreye, Allam, Mayar, Schneider, Frank, Ramalingam, Suresh S., Sun, Shi-Yong, Coskun, Ahmet F.
Publicado 2022

Efficacy and Safety of Glembatumumab Vedotin in Patients With Advanced or Metastatic Squamous Cell Carcinoma of the Lung (PrECOG 0504)

por Khan, Saad A., Sun, Zhuoxin, Dahlberg, Suzanne, Malhotra, Jyoti, Keresztes, Roger, Ikpeazu, Chukwuemeka, Ma, Patrick, Ramalingam, Suresh S., Pillai, Rathi
Publicado 2021

An open label randomized Phase III trial of nivolumab or nivolumab plus ipilimumab vs platinum doublet chemotherapy (PT-DC) in patients with chemotherapy-naïve stage IV or recurren...

por Hellmann, Matthew, Ramalingam, Suresh, Reck, Martin, O'Byrne, Ken, Paz-Ares, Luis, Harbison, Christopher T, Bhagavatheeswaran, Prabhu, Nathan, Faith, Brahmer, Julie
Publicado 2015

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

por Xu, Ke, Park, Dongkyoo, Magis, Andrew T., Zhang, Jun, Zhou, Wei, Sica, Gabriel L., Ramalingam, Suresh S., Curran, Walter J., Deng, Xingming
Publicado 2019

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy

por Xu, Ke, Park, Dongkyoo, Magis, Andrew T., Zhang, Jun, Zhou, Wei, Sica, Gabriel L., Ramalingam, Suresh S., Curran, Walter J., Deng, Xingming
Publicado 2020